BioCentury
ARTICLE | Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

How Revolution Medicines plans to deploy Boxer Capital-led series C to advance portfolio of Ras pathway inhibitors

July 9, 2019 11:30 AM UTC

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor.

The financing, announced Tuesday, was led by Boxer Capital of the Tavistock Group. Also participating were Cormorant Capital, Deerfield Management, Fidelity Management & Research Co., Vivo Capital and Biotechnology Value Fund, as well as all series B investors, including Nextech Invest, Schroder Adveq, The Column Group, Third Rock Ventures and Casdin Capital...